The company will use the offering to help finance the $4.5 billion acquisition of Omega Pharma.
OTC pharmaceutical company Perrigo Company (NYSE:PRGO; TASE:PRGO) has filed a prospectus with the US Securities and Exchange Commission (SEC) to raise $900 million in a secondary offering on Wall Street. The funds will be used to help acquire Belgian OTC manufacturer Omega Pharma for $4.5 billion, which Perrigo announced earlier this month.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
At the current price of Perrigo’s share, the offering represents a 4.5% stake in the company. Perrigo had cash reserves of $862 million at the end of the last quarter. The company, managed by President and CEO Joseph Papa, has a market cap of $21.3 billion.
Published by Globes [online], Israel business news – www.globes-online.com